Dr. Scott Rocklage has spent over three decades within the healthcare industry. Dr. Rocklage received his bachelors degree in Chemistry from the University of California, Berkeley. He continued his education at MIT, where he received his Ph.D. in Chemistry and engaged in laboratory research under Nobel Prize winner, Richard R. Schrock. Under Scott Rocklage’s management expertise and leadership capabilities, his efforts led to the FDA’s successful approval of three new U.S. drug applications, Cubicin, Teslascan, and Omniscan.
Scott joined 5AM Ventures in 2003 as a Venture Partner, and in 2004 he became the company’s Management Partner. 5AM Ventures focuses on offering seed money and investments to clients within the world of biopharmaceuticals and medical technology. Finding solutions and pushing innovation within the life sciences, supporting biomedical technology, and working closely alongside firms of interest is key to 5AM Ventures. Dr. Scott Rocklage has a lengthy history of holding various leadership responsibilities and titles within the healthcare industry. He was the Chairman and CEO of Cubist Pharmeceuticals, and formerly served as the Board Chairman for Novira and Relypsa companies. Dr. Rocklage was also the former Executive Chairman of Miikana, Ilypsa, and Semprus. All of these companies have since been acquired by other companies within the pharmaceutical industry.
Dr. Scott Rocklage, in addition to his history within the healthcare industry as a strategic leader who gets pharmaceutical drugs into and beyond testing phases, is also an inventor or co-inventor of over 30 different patents within the United States. He has been noted in over 100 various peer-reviewed publications.